Investment House LLC Sells 857 Shares of Eli Lilly and Company (NYSE:LLY)

Investment House LLC lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 47,670 shares of the company’s stock after selling 857 shares during the period. Eli Lilly and Company accounts for approximately 2.0% of Investment House LLC’s holdings, making the stock its 11th biggest position. Investment House LLC’s holdings in Eli Lilly and Company were worth $36,802,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in LLY. North Forty Two & Co. purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $505,000. VSM Wealth Advisory LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $1,357,000. Enhancing Capital LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $6,408,000. Halter Ferguson Financial Inc. raised its position in shares of Eli Lilly and Company by 16.6% during the 4th quarter. Halter Ferguson Financial Inc. now owns 6,801 shares of the company’s stock valued at $5,250,000 after buying an additional 968 shares in the last quarter. Finally, Generali Asset Management SPA SGR purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $54,907,000. Institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on LLY shares. Berenberg Bank set a $970.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, January 16th. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Citigroup reduced their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Morgan Stanley set a $1,146.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, March 6th. Finally, Bank of America reissued a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,009.72.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Down 0.4 %

NYSE:LLY opened at $821.67 on Wednesday. Eli Lilly and Company has a 12 month low of $711.40 and a 12 month high of $972.53. The firm has a fifty day simple moving average of $833.02 and a 200-day simple moving average of $840.71. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The company has a market capitalization of $779.08 billion, a P/E ratio of 70.17, a PEG ratio of 1.40 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company declared that its Board of Directors has initiated a stock buyback program on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to reacquire up to 2% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.